In-Med Prognostics L3C
About In-Med Prognostics L3C
In-Med Prognostics L3C is a healthcare AI company focused on providing affordable, accessible, and evidence-based brain health diagnostic tools, particularly for emerging markets. The company leverages deep learning algorithms and machine learning to offer neuro analysis that aids in the assessment and early detection of neurological disorders such as Dementia, Alzheimer’s, and Parkinson’s disease. Their proprietary software, NeuroShield™, integrates MRI images, clinical reports, and psychological assessments to produce automated, quantified reports, supporting physicians in their clinical impressions.
In-Med Prognostics offers several software solutions, including NeuroFlo, a neurology workflow platform; NeuroShield, an AI-based application providing ethnicity-specific volumetric analysis reports of the brain within 20 minutes; and VivoShield Sports, an AI-powered platform for precision analysis in sports medicine. The company’s technology is designed to enhance radiologist workflow and provide neurologist decision support. In November 2023, InMed.AI (InMed Prognostics Inc.) received US FDA 510(k) clearance for NeuroShield™, which automatically quantifies brain volumes using MRI data and is noted as the first of its kind with the capability to provide ethnicity-specific reference ranges.
Focus Areas
Business Intelligence
| Technology | Cloud-based, AI/Deep Net/3D Convolutional Networks, automated image processing algorithms, AI/ML pipelines, multi-modal data (text, signal, image) |
What Physicians Need to Know
For physicians, In-Med Prognostics' tools offer several advantages:
* **Early & Accurate Diagnosis:** NeuroShield's AI-powered volumetry and ethnicity-specific reference ranges can aid in earlier and more precise diagnosis of neurodegenerative diseases, potentially allowing for timely interventions.
* **Enhanced Decision Support:** The platforms provide objective, quantitative data and automated reports, supporting evidence-based clinical decision-making for various neurological conditions and neurotrauma.
* **Reduced Workload & Optimized Workflow:** NeuroFlo and the automated analysis capabilities can significantly reduce the manual burden on radiologists and streamline clinical operations, improving efficiency.
* **Precision Medicine:** The inclusion of ethnicity-specific reference ranges ensures more equitable and personalized diagnostic insights, particularly beneficial for diverse patient populations.
* **Global Accessibility:** The company's mission to provide affordable and accessible tools, especially in emerging markets, broadens the reach of advanced brain health diagnostics.
In-Med Prognostics' cloud-based platforms are designed for seamless integration into existing clinical workflows, offering compatibility with multi-scanner environments and providing centralized data visualization and report automation. They are actively used in over 220 clinical sites worldwide.
What the Web Says
In-Med Prognostics L3C (also known as InMed.AI) is a health tech company founded in 2018 that specializes in AI-driven predictive analytics for neurological disorders. Their flagship product, NeuroShield, is an FDA 510(k) cleared AI brain volumetry and neurotrauma decision-support tool that uses 3D MRI images to quantify brain volumes and assist in diagnosing and devising treatment plans for neurodegenerative diseases like Dementia, Alzheimer's, Parkinson's, and Epilepsy. The company has a global presence, with NeuroShield in clinical use in over 220 sites across the world, including India, Africa, and the Middle East. They are also expanding into CT Brain applications, Whole Body MRI/video Wellness/Athletic solutions, and lesion solutions for pancreatic and liver cancer.
Overall: PositiveStrengths
- NeuroShield is FDA 510(k) cleared.
- NeuroShield provides fully automated brain volumetry using AI/Deep Net/3D Convolutional Networks.
- The technology has shown high accuracy across various scanners, clinical subgroups, genders, ages, slice thicknesses, and geographic regions.
- NeuroShield is the first in the world to offer age, gender, and ethnicity-adjustable reference ranges, promoting precision medicine.
- The product aims to reduce radiologists' burden and provide affordable, accessible, and reliable healthcare tools.
- In-Med Prognostics is actively expanding its product portfolio and global reach.
Limitations
- No specific product reviews from G2, Glassdoor, Capterra, or Reddit were found.
- No specific employer reviews from Glassdoor were found for "In-Med Prognostics L3C" (reviews for similarly named companies like "InMed Diagnostic Services" and "InMed Group" exist but are not confirmed to be the same entity).
- Limited public information on company culture or employee sentiment specific to In-Med Prognostics L3C.
- The cost of the NeuroShield product is not readily available in the provided search results.
- The company is relatively young (founded in 2018), which may mean fewer long-term reviews are available.
Based on reviews from: InMed.AI, BioSpace, MobiHealthNews, Health.economictimes.indiatimes.com, PitchBook, RSNA 2023: In-Med Prognostics, Indeed.com, G2, Capterra, Reddit
Last updated: 2026-10-20
Videos
News, demos, and interviews about In-Med Prognostics L3C.
Videos load interactively. If none appear, search YouTube for In-Med Prognostics L3C →
Press & Coverage
Frequently Asked Questions
Related Companies
Perimeter Medical Imaging AI is a medical technology company dedicated to transforming cancer surgery through the use of ultra-high-resolution, real-time, advanced imaging tools. The company’s mission is to address significant unmet medical needs in cancer surgery, particularly concerning positive margins and the resulting need for re-excisions. Their proprietary technology, including the S-Series Optical Coherence Tomography […]
SOPHiA GENETICS is a healthcare AI company that has developed a cloud-native, AI-driven SaaS platform called SOPHiA DDM™. This platform is designed to enable hospitals, clinical laboratories, academic medical centers, and biopharmaceutical companies to analyze and interpret complex genomic, radiomic, and multimodal healthcare data. The company’s mission is to democratize data-driven medicine, providing actionable insights […]
Koios Care is a neurology-focused digital medicine company based in Antwerp, Belgium, specializing in AI-powered platforms. The company aims to revolutionize the management of neurological and chronic conditions, with an initial focus on Parkinson’s Disease. Koios Care’s platform utilizes everyday devices like smartphones and smartwatches to passively collect and analyze data, transforming it into objective, […]
Qure.ai is a leading healthcare AI company that leverages deep learning and artificial intelligence to revolutionize medical imaging diagnostics and make healthcare more accessible and affordable globally. The company develops AI-powered solutions for interpreting X-rays and CT scans, addressing critical health needs in areas such as lung, musculoskeletal, cardiovascular, and neurocritical health. Their technology assists […]
Deep Bio is a healthcare AI company that develops deep learning-based cancer diagnostic support software, aiming to advance patient outcomes by empowering clinicians with innovative technology. Their mission is to provide tools that enable medical professionals to make critical decisions, ultimately enhancing healthcare delivery and allowing clinicians to focus more on patient care. The company’s […]
CortiCare is a healthcare AI company specializing in neuro telemetry and remote patient monitoring, primarily focusing on electroencephalogram (EEG) services. The company provides telehealth services and an EEG brain monitoring platform to neurology and critical care areas within hospitals, including ICUs, NICUs, PICUs, and EMUs. Their services aim to enhance the neurological assessment of adult, […]